INVITES BIOCORE CO., LTD

216400KONEXResearch and development

INVITES BIOCORE CO., LTD (216400, KONEX) reported KRW 17bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2023
2024220-119814Consolidated
2025170-8833Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023
20241.5%-49.7%14.1%-77.6%
20251.3%-49.9%3.2%-312.7%

Revenue moved -23.1% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 11bn
Close priceKRW 1,440
Listed shares7,711,315
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)133
Women80 (60.2%)
Average tenure3.8 years
Annual pay, menKRW 55,273,000
Annual pay, womenKRW 45,224,000
Pay ratio, women to men81.8%

Other companies in Research and development

63 listed companies file under this classification. Showing 12.

See the whole Research and development list →